文献速递颈动脉与弓上血管

无症状颈动脉内膜切除术后预期寿命预测评分的开发与验证

Development and validation of a score to predict life expectancy after carotid endarterectomy in asymptomatic patients.
PubMed 文献 · J Vasc Surg · 2017-09-21

基于单中心648例无症状颈动脉狭窄患者的回顾性分析开发术后生存预测评分,并在两院334例患者中外部验证。评分将患者分为4组,5年生存率从97%至48.1%梯度下降,验证队列结果高度一致,提示该简易工具可辅助筛选适合CEA的患者。

要点

  • 评分含年龄、肾功能、透析及心肺合并症与他汀使用,分值0-12分以上。
  • derivation队列5年生存率组1为97%,组4仅48.1%(P<.0001)。
  • 验证队列各组生存曲线与 derivation队列高度相似,评分可快速预测生存。

核心结论

  • 该评分是简易临床工具,可快速可靠预测无症状CEA候选患者的术后生存。

研究设计与样本

  • 回顾性分析单中心648例连续无症状患者开发评分,并在两院334例无症状患者中外部验证。

主要发现

  • derivation队列与验证队列中位随访分别为56和65个月,5年生存率分别为84.7%±1.7%和85.2%±2%(P=.41)。
  • derivation队列5年生存率:组1 97%±1.5%,组2 88.4%±2.2%,组3 69.6%±4.7%,组4 48.1%±13.5%(P<.0001)。
  • 验证队列5年生存率:组1 95.5%±2%,组2 89.5%±2.7%,组3 65%±6.1%,组4 44.8%±14.1%(P<.0001)。
  • 两队列组特异性生存曲线高度相似。

关键数值与推荐

  • 评分赋值:COPD、糖尿病、冠心病、未使用他汀各1分;年龄70-79岁和肌酐≥1.5 mg/dL各4分;年龄≥80岁和透析各8分。
  • 风险分组:组1 0-3分,组2 4-7分,组3 8-11分,组4 ≥12分。

临床怎么用

  • 可用于无症状颈动脉狭窄患者CEA术前筛选,避免对预期生存不足者行预防性手术。

局限性

  • 回顾性设计,样本来自同一地区医院,外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recent improvement of best medical treatment for carotid stenosis has sparked a debate on the role of surgery-identification of patients who may benefit from carotid endarterectomy (CEA) is crucial to avoid overtreatment. An expected 5-year postoperative survival is one of the main selection criteria. The aim of this study was the development of a score for predicting survival of asymptomatic patients after CEA. METHODS: Our score was derived from a retrospective analysis of 648 consecutive asymptomatic patients from a single hospital. External validation of the score was then performed on a second cohort of 334 asymptomatic patients from two different hospitals in the same area. Factors associated with reduced postoperative survival within the derivation cohort (DC) were identified and tested for statistical significance. Each selected factor was assigned a score proportional to its β coefficient: 1 point for chronic obstructive pulmonary disease, diabetes mellitus, coronary artery disease, and lack of statin treatment; 4 points for age 70 to 79 years and creatinine concentration ≥1.5 mg/dL; 8 points for age ≥80 years and dialysis. The DC was divided into four groups based on individual scores: group 1, 0 to 3 points; group 2, 4 to 7 points; group 3, 8 to 11 points; and group 4, ≥12 points. Group-specific survival curves were calculated. The validation cohort (VC) was stratified according to the score. Survival of each of the four risk groups within the VC was compared with its analogue from the DC. RESULTS: Median follow-up of the DC and VC was, respectively, 56 and 65 months. Intercohort comparison of 5-year survival was 84.7% ± 1.7% vs 85.2% ± 2% (P = .41). Group-specific 5-year survival within the DC was 97% ± 1.5% (group 1), 88.4% ± 2.2% (group 2), 69.6% ± 4.7% (group 3), and 48.1% ± 13.5% (group 4; P < .0001). Five-year survival within the VC was 95.5% ± 2% (group 1), 89.5% ± 2.7% (group 2), 65% ± 6.1% (group 3), and 44.8% ± 14.1% (group 4; P < .0001). Intercohort comparison of group-specific survival curves showed close similarity throughout the groups. CONCLUSIONS: Our score is a simple clinical tool that allows a quick and reliable prediction of survival in asymptomatic patients who are candidates for CEA. This selective approach is crucial to avoid unnecessary surgery on patients who are less likely to survive long enough to experience the benefits of this preventive procedure.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Carmo M, Barbetta I, Bissacco D, et al. Development and validation of a score to predict life expectancy after carotid endarterectomy in asymptomatic patients. J Vasc Surg. 2017. PMID: 28943008. doi:10.1016/j.jvs.2017.05.107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。